Saxenda Injection, Solution
Product Images NDC 0169-2800

45 FDA label images from Novo Nordisk Pharmaceutical Industries, Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 45 technical images submitted to the FDA as part of the official labeling for Saxenda (NDC 0169-2800). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk Pharmaceutical Industries, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural-formula (Image 01)

Structural-formula (Image 01)
Chemical structure diagram showing the amino acid sequence of liraglutide, the active ingredient in Saxenda 6 mg/mL injection. The sequence is depicted as connected circles labeled with one-letter amino acid codes and includes an attached C-16 fatty acid (palmitoyl) group.*
FDA Label Image

Figure-2 (Image 09)

Figure-2 (Image 09)
This image shows two side-by-side cumulative frequency plots comparing Saxenda and placebo groups. Both graphs depict the distribution of percent change in body weight, with the horizontal axis representing change in body weight (%) ranging from -30 to 20, and the vertical axis representing cumulative frequency (%). Saxenda curves show a left-shift indicating greater weight reduction compared to placebo. The data is from an ITT analysis with multiple imputations.*
FDA Label Image

Figure-3 (Image 10)

Figure-3 (Image 10)
Two line graphs depicting changes in body weight (%) over weeks for Saxenda (liraglutide) 6 mg/mL injection solution compared to placebo. The left chart shows data for a larger patient group over 56 weeks, with Saxenda showing a weight decrease up to -9.2%. The right chart shows a smaller group also up to 56 weeks, with Saxenda weight decrease up to -6.7%. Both charts include patient counts (N) for Saxenda and placebo groups.*
FDA Label Image

Figure-4 (Image 12)

Figure-4 (Image 12)
This line graph compares the percentage change in body weight over a 56-week period between patients using Saxenda (liraglutide) and a placebo, both groups initially on a low-calorie diet. Saxenda shows a steady decrease in body weight reaching approximately -6.8% by week 56, while placebo shows minimal weight change near 0%. Patient numbers at various weeks are indicated for both groups, highlighting data completeness.*
FDA Label Image

Figure-5 (Image 02)

Figure-5 (Image 02)
A line graph comparing body mass index standard deviation score (BMI SDS) changes from baseline over time (weeks) between Saxenda and placebo groups. The x-axis shows weeks since randomization, and the y-axis displays BMI SDS change from baseline, with error bars representing standard error. Saxenda shows a steady decrease in BMI SDS compared to placebo.*
FDA Label Image

Qr-code (Image 44)

FDA Label Image

Note (Image 03)

Note (Image 03)
Packaging label for Saxenda 6 mg/mL solution for injection (liraglutide) by Novo Nordisk Pharmaceutical Industries, LP. It shows the outer carton design including usage instructions, support website, barcodes, and branding. The product is a subcutaneous human prescription drug in a 3 mL prefilled pen.*
FDA Label Image

Pen_image (Pen Image)

Pen_image (Pen Image)
Illustration of Saxenda pen injection components and controls for the 6 mg/mL liraglutide solution by Novo Nordisk. The pen includes a pen cap, dose selector, dose button, dose counter, dose pointer, pen scale, and pen window. Separate parts of the needle assembly are shown: outer needle cap, inner needle cap, needle, and a paper tab. The flow check symbol on the dose selector is also depicted.*
FDA Label Image

Image_a (Image A)

Image_a (Image A)
An instructional illustration showing two hands pulling apart or twisting a protective cap or cover from a small cylindrical device or pen, indicated by an arrow pointing away from one hand. The image suggests a step in the preparation or assembly of an injection device, likely related to Saxenda liraglutide injection.*
FDA Label Image

Image_b (Image B)

Image_b (Image B)
An instructional illustration showing a hand holding a Saxenda 6 mg/mL injection pen, focusing on the pen's dose window and tip. The image highlights proper handling of the subcutaneous injection device for liraglutide by Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Image_c (Image C)

Image_c (Image C)
An instructional illustration showing hands removing a cap from the tip of an injection pen device, indicating preparation steps for subcutaneous injection, likely related to Saxenda (liraglutide) injection, solution 6 mg/mL by Novo Nordisk.*
FDA Label Image

Image_d (Image D)

Image_d (Image D)
An instructional illustration showing a hand gripping a syringe pen, turning the pen's gray dial or cap. This image likely demonstrates a step in preparing or using the Saxenda injection pen (liraglutide) for subcutaneous administration.*
FDA Label Image

Image_e (Image E)

Image_e (Image E)
An instructional illustration showing a hand removing a protective cap from the needle of an injection pen, likely related to the preparation of Saxenda (liraglutide) injection for subcutaneous use.*
FDA Label Image

Note (Image 13)

Note (Image 13)
Saxenda 6 mg/mL injection solution in a multidose pen package. The label includes the product name Saxenda, active ingredient liraglutide, and specifies it is a subcutaneous injection. The labeler is Novo Nordisk Pharmaceutical Industries, LP. The packaging shows storage instructions and warnings commonly found on medicinal injection pens.*
FDA Label Image

Info (Image 14)

Info (Image 14)
Saxenda 6 mg/mL injection, solution for subcutaneous use in a pen injector device. The label displays the proprietary name Saxenda, the generic name liraglutide, and the strength 6 mg/mL. The packaging shows Novo Nordisk Pharmaceutical Industries, LP as the labeler. The image is of the product packaging and pen injector designed for single-patient use.*
FDA Label Image

Image_f (Image F)

Image_f (Image F)
An instructional illustration showing a hand removing a cap from the tip of a prefilled pen injector. The image is part of usage instructions for Saxenda (liraglutide) injection, 6 mg/mL, a subcutaneous solution by Novo Nordisk Pharmaceutical Industries.*
FDA Label Image

Flow-check (Image 16)

Flow-check (Image 16)
Saxenda 6 mg/mL injection solution in a prefilled pen, labeled for subcutaneous use. The packaging displays the Novo Nordisk Pharmaceutical Industries, LP logo and branding. The pen is primarily white with a label indicating it contains liraglutide.*
FDA Label Image

Image_g (Image G)

Image_g (Image G)
An instructional illustration showing hands holding a Saxenda injection pen for flow check. The image depicts the step to verify the flow check symbol on the dose window, indicating readiness for injection.*
FDA Label Image

Note (Image 18)

Note (Image 18)
Saxenda 6 mg/mL injection solution in a 3 mL pre-filled pen syringe. The label displays the brand name Saxenda, the generic name liraglutide, and strength 6 mg/mL. It indicates subcutaneous use and is produced by Novo Nordisk Pharmaceutical Industries, LP. The packaging shows the product as a human prescription drug.*
FDA Label Image

Info (Image 19)

Info (Image 19)
Saxenda 6 mg/mL injection, solution in a 3 mL multi-dose pen. The label shows the brand name Saxenda, active ingredient liraglutide, and the strength 6 mg/mL. It is intended for subcutaneous use and is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The pen is depicted with dosing markings on the side.*
FDA Label Image

Image_h (Image H)

Image_h (Image H)
Instructional diagram showing a hand holding a Saxenda (liraglutide) injection pen with an arrow indicating to pull the pen cap upward to remove it. The inset highlights the pen cap for clarity.*
FDA Label Image

Note (Image 21)

Note (Image 21)
Saxenda 6 mg/mL injection, solution in a cartridge package. The label indicates it is for subcutaneous use and is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The packaging highlights the proprietary name Saxenda and generic name liraglutide. The package also shows the Novo Nordisk logo on the side.*
FDA Label Image

Info (Export 03)

Info (Export 03)
Saxenda 6 mg/mL injection solution in a box with a pre-filled pen visible. The label shows the brand name Saxenda and the active ingredient liraglutide. The product is for subcutaneous use and manufactured by Novo Nordisk Pharmaceutical Industries, LP. The packaging displays dosage strength and includes usage instructions on the pen.*
FDA Label Image

Image_i (Image I)

Image_i (Image I)
Illustration showing a close-up of a Saxenda injection pen with a dial set to 0.6 mg dose. Hands are depicted holding the pen, demonstrating selection of the 0.6 mg liraglutide dosage for subcutaneous injection.*
FDA Label Image

Info (Image 24)

Info (Image 24)
Saxenda 6 mg/mL injection solution label for subcutaneous use. The label features the brand name 'Saxenda' prominently with the active ingredient liraglutide. It indicates the product is a human prescription drug. The label includes concentration details and the labeler’s name, Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Image_j (Image J)

Image_j (Image J)
An instructional illustration showing a close-up view of a dose indicator on a syringe-like device, with the display reading 'Example Approx. 3 mg left,' likely representing the remaining dosage to be administered from the injection pen.*
FDA Label Image

Info (Image 26)

Info (Image 26)
Saxenda 6 mg/mL injection, solution in a prefilled pen device. The label shows the Saxenda brand name, the generic name liraglutide, and indicates subcutaneous use. The labeler is Novo Nordisk Pharmaceutical Industries, LP. The pen is designed for human prescription drug use.*
FDA Label Image

Note (Image 27)

Note (Image 27)
Saxenda 6 mg/mL injection solution carton label for subcutaneous use. The packaging features the brand name Saxenda prominently along with the generic name liraglutide, strength, dosage form, and labeler Novo Nordisk Pharmaceutical Industries, LP. The design includes blue and white color blocks with key product information displayed on the front.*
FDA Label Image

Image_k (Image K)

Image_k (Image K)
An instructional diagram showing a close-up of a Saxenda (liraglutide) pen-injector dose counter stopping at 2.4 mg, with a hand holding the device and an arrow indicating the dose display. The text notes the example dose count stopped at 2.4 mg left.*
FDA Label Image

Image_l (Image L)

Image_l (Image L)
An instructional illustration showing recommended subcutaneous injection sites for Saxenda (liraglutide) on a simplified human figure. Highlighted areas include the upper arms, stomach, and thigh, indicating where the medication can be injected.*
FDA Label Image

Image_m (Image M 01)

Image_m (Image M 01)
An instructional illustration showing a hand holding an injection pen labeled 'M', poised for subcutaneous injection. The pen is positioned above an area of skin with an arrow pointing downward, indicating the direction for administering the medication.*
FDA Label Image

Image_n (Image N)

Image_n (Image N)
Instructional illustration showing a hand holding a Saxenda injection pen, positioned for subcutaneous injection. An arrow indicates the motion to press the pen downward to administer the dose. The dose window displays '0 mg.'*
FDA Label Image

Image_o (Image O)

Image_o (Image O)
An instructional diagram showing a hand holding an injection pen for subcutaneous use. The illustration advises to count slowly from 1 to 6 while administering the injection, indicating a timed and controlled injection process.*
FDA Label Image

Note (Export 02)

Note (Export 02)
Saxenda 6 mg/mL injection solution package label from Novo Nordisk Pharmaceutical Industries, LP. The label includes product information, strength, dosage form (subcutaneous injection), and branding details on a predominantly red and white background.*
FDA Label Image

Info (Export 01)

Info (Export 01)
Saxenda 6 mg/mL solution for injection vial label by Novo Nordisk Pharmaceutical Industries, LP. The label indicates it is a human prescription drug with subcutaneous administration. The vial label includes brand and generic names, concentration, and regulatory information.*
FDA Label Image

Image_p (Image P 01)

Image_p (Image P 01)
An instructional illustration showing a subcutaneous injection device, presumably a pen, with an upward-pointing arrow above the needle area, indicating the action of pulling or lifting. The blue background and white border frame the visual guidance for use.*
FDA Label Image

Image_q (Image Q 01)

Image_q (Image Q 01)
An instructional illustration showing a hand removing a protective cap from the top of a pen injector. The pen has a purple body with dosage markings, indicating it is part of a subcutaneous injection device, such as for Saxenda (liraglutide). An arrow indicates the direction to twist or pull the cap off.*
FDA Label Image

Image_r (Image R)

Image_r (Image R)
An instructional illustration showing a vial with a rubber stopper and an arrow indicating the insertion of a needle through the stopper, likely demonstrating the step to access the injection solution.*
FDA Label Image

Image_s (Image S)

Image_s (Image S)
An instructional illustration showing a close-up of hands preparing a pen-style injection device, likely demonstrating the step to remove a protective cap or to prime the injection. The image is associated with Saxenda (liraglutide) 6 mg/mL injection, solution for subcutaneous use by Novo Nordisk Pharmaceutical Industries.*
FDA Label Image

Info (Export 00)

Info (Export 00)
Packaging label of Saxenda 6 mg/mL injection, solution for subcutaneous use. The label includes branding for Saxenda and highlights liraglutide as the active ingredient. It shows the labeler as Novo Nordisk Pharmaceutical Industries, LP and displays product information suitable for prescription use.*
FDA Label Image

Note (Image 39)

Note (Image 39)
Saxenda 6 mg/mL injection solution in a 3 mL glass vial with a gray cap. The label shows the brand name Saxenda, active ingredient liraglutide, and dosage strength. The vial is produced by Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Info (Image 40)

Info (Image 40)
Saxenda 6 mg/mL injection solution in a subcutaneous form. The packaging displays the product name Saxenda prominently, with liraglutide as the active ingredient. The label includes the labeler, Novo Nordisk Pharmaceutical Industries, LP, and the FDA-assigned NDC 0169-2800. The image shows a carton packaging for the prescription drug.*
FDA Label Image

Image_t (Image T 01)

Image_t (Image T 01)
An instructional diagram showing the attachment of a needle to a syringe or pen device. It depicts a needle cap being aligned and pushed onto the syringe or pen tip, indicated by two arrows pointing toward each other, illustrating the needle connection process.*
FDA Label Image

Note (Image 42)

Note (Image 42)
Saxenda 6 mg/mL injection solution in a prefilled pen device. The label shows the brand name Saxenda prominently, with liraglutide as the generic name. The product is indicated for subcutaneous use. The pen is white and orange with dosage markings, alongside its instruction leaflet. The labeler is Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Trade_carton (Trade Carton)

Trade_carton (Trade Carton)
Packaging label for Saxenda injection (liraglutide) 18 mg/3 mL (6 mg/mL) solution in 5 x 3 mL prefilled pens by Novo Nordisk Pharmaceutical Industries, LP. The label includes dosage form, strength, instructions for subcutaneous use, storage conditions, ingredients, and regulatory information with Novo Nordisk logo and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.